Pediatric Endocrinology-Diabetology Department, Reference Center for Rare Growth and Development Endocrine Diseases, INSERM NeuroDiderot, Assistance Publique-Hôpitaux de Paris, Université de Paris, Robert Debré University Hospital, 48 Bd Sérurier, 75019, Paris, France.
Department of Reproductive Endocrinology, Reference Center for Rare Growth and Development Endocrine Diseases, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Saint Antoine Hospital, 75012, Paris, France.
Orphanet J Rare Dis. 2022 Jul 12;17(Suppl 1):261. doi: 10.1186/s13023-022-02423-5.
Turner syndrome (TS; ORPHA 881) is a rare condition in which all or part of one X chromosome is absent from some or all cells. It affects approximately one in every 1/2500 liveborn girls. The most frequently observed karyotypes are 45,X (40-50%) and the 45,X/46,XX mosaic karyotype (15-25%). Karyotypes with an X isochromosome (45,X/46,isoXq or 45,X/46,isoXp), a Y chromosome, X ring chromosome or deletions of the X chromosome are less frequent. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins) is to provide health professionals with information about the optimal management and care for patients, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Growth and Developmental Endocrine disorders, is available from the French Health Authority website. Turner Syndrome is associated with several phenotypic conditions and a higher risk of comorbidity. The most frequently reported features are growth retardation with short adult stature and gonadal dysgenesis. TS may be associated with various congenital (heart and kidney) or acquired diseases (autoimmune thyroid disease, celiac disease, hearing loss, overweight/obesity, glucose intolerance/type 2 diabetes, dyslipidemia, cardiovascular complications and liver dysfunction). Most of the clinical traits of TS are due to the haploinsufficiency of various genes on the X chromosome, particularly those in the pseudoautosomal regions (PAR 1 and PAR 2), which normally escape the physiological process of X inactivation, although other regions may also be implicated. The management of patients with TS requires collaboration between several healthcare providers. The attending physician, in collaboration with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. The various elements of this PNDS are designed to provide such support.
特纳综合征(TS;ORPHA881)是一种罕见的疾病,部分或全部细胞中一条 X 染色体缺失或部分缺失。它影响大约每 2500 名活产女婴中就有 1 名。最常观察到的核型是 45,X(40-50%)和 45,X/46,XX 嵌合体核型(15-25%)。带有 X 等臂染色体(45,X/46,isoXq 或 45,X/46,isoXp)、Y 染色体、X 环状染色体或 X 染色体缺失的核型则较少见。法国国家诊断和护理协议(PNDS;Protocole National de Diagnostic et de Soins)的目的是为卫生专业人员提供有关患者最佳管理和护理的信息,这是基于对文献的批判性回顾和多学科专家共识。该协议由法国国家罕见生长和发育内分泌障碍参考中心的成员撰写,可从法国卫生署网站获得。特纳综合征与多种表型疾病和更高的合并症风险相关。最常报告的特征是生长迟缓导致成年身高矮小和性腺发育不全。TS 可能与各种先天性(心脏和肾脏)或后天性疾病(自身免疫性甲状腺疾病、乳糜泻、听力损失、超重/肥胖、葡萄糖耐量/2 型糖尿病、血脂异常、心血管并发症和肝功能障碍)相关。TS 的大多数临床特征是由于 X 染色体上各种基因的单倍体不足,特别是那些在假常染色体区域(PAR1 和 PAR2)的基因,这些基因通常会逃避 X 失活的生理过程,尽管其他区域也可能涉及。TS 患者的管理需要多个医疗保健提供者的合作。主治医生将与国家护理网络合作,通过定期随访和筛查,确保患者获得最佳护理。该 PNDS 的各个部分旨在提供这种支持。